Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
HER2 Antibodies Market: By Drug Type, By Distribution Channel, and Region Forecast 2019-2030
HER2 Antibodies Market: By Drug Type, By Distribution Channel, and Region Forecast 2019-2030
HER2 antibodies market Size was valued at US$ 10.6 Bn in 2023, growing at a significant CAGR of 8.6% over the forecast period 2024 to 2030. HER2 antibodies are the products used in the treatment of HER2 positive breast cancer HER2 is the member of human epidermal growth factor family. Over-expression of HER2 oncogene leads to development and progression of certain types of aggressive breast cancer. Rise in incidence of HER2 positive breast cancer around the globe, rise in R&D for the innovation of newer drugs for HER2 positive breast cancer treatment, promising pipeline products for the treatment, government initiations for breast cancer awareness among the masses, and advanced techniques for HER2 positive breast cancer diagnosis are expected to upsurge the revenue of global HER2 antibodies market over the forecast years.
However, high cost of drugs, adverse effects associated with drugs, and fewer produts availability in the market may restrain the growth of global HER2 antibodies market. The HER protein and growth factor family is made up of four members, each with its own set of functions. Herceptin (Trastuzumab) binds to HER-two (HER-alphaextracellular )'s domain, preventing it from attaching to other receptors including insulin-like growth factor receptors (IGF/IR). Trastuzumab was first developed in 1998 for the treatment of metastatic breast cancer, but it has since been discovered to have other applications.
Study Period
2024-2030Base Year
2023CAGR
8.6%Largest Market
North AmericaFastest Growing Market
Europe
The protein on the cell surface that helps the cell develop is controlled by the human epidermal growth factor receptor 2 (HER2). It is a member of the epidermal growth factor receptor family. It's a tyrosine kinase receptor with a transmembrane structure. The expansion of the tumour is caused by alterations in HER2. When the HER2 gene is expressed in more than two cells, an excessive amount of HER2 protein is produced, which is known as overexpression of HER2. HER2 expression has been found on epithelial cell membranes in the gastrointestinal tract, skin, breast, urinary tract, placenta, skeleton muscle cells, and the heart. HER2 expression is generally higher in fatal tissue than in normal adult tissue. Overexpression of the HER2 protein causes HER2 breast cancer, which is one of the most dangerous kinds of breast cancer.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market growth driven by increase in the prevalence of HER2 positive breast cancer (according to American Cancer Society 2017, about 252,710 women are effected with breast cancer in U.S. with approximately 1 in 5 women are sufferng from HER2 positive breast cancer), rise in R&D for the innovation of newer drugs, and increase in healthcare expenditure. Europe market has a lucrative growth opportunities owing to prevalence of HER2 positive breast cancer, high adoption of newer drugs, and regulatory support from cancer associations are expected to bolster the market. However, growth of Asia Pacific market driven by rise in medical tourism in Asia Pacific region, advances in healthcare infrastructure for the disease diagnosis, and entry of market players into Asia Pacific region are expected to upsurge the revenue of market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
8.6% |
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
HER2 antibodies market Size was valued at US$ 10.6 Bn in 2023, growing at a significant CAGR of 8.6% over the forecast period 2024 to 2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global HER2 Antibodies Market Introduction |
| 2.1.Global HER2 Antibodies Market - Taxonomy |
| 2.2.Global HER2 Antibodies Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global HER2 Antibodies Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global HER2 Antibodies Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global HER2 Antibodies Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Pertuzumab |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Trastuzumab |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Ado-trastuzumab emtansine |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Lapatinib |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Everolimus |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global HER2 Antibodies Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global HER2 Antibodies Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America HER2 Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Pertuzumab |
| 8.1.2.Trastuzumab |
| 8.1.3.Ado-trastuzumab emtansine |
| 8.1.4.Lapatinib |
| 8.1.5.Everolimus |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Retail Pharmacies |
| 8.2.3.Online Pharmacies |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe HER2 Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Pertuzumab |
| 9.1.2.Trastuzumab |
| 9.1.3.Ado-trastuzumab emtansine |
| 9.1.4.Lapatinib |
| 9.1.5.Everolimus |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Retail Pharmacies |
| 9.2.3.Online Pharmacies |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10.Asia Pacific (APAC) HER2 Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Pertuzumab |
| 10.1.2.Trastuzumab |
| 10.1.3.Ado-trastuzumab emtansine |
| 10.1.4.Lapatinib |
| 10.1.5.Everolimus |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Retail Pharmacies |
| 10.2.3.Online Pharmacies |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) HER2 Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Pertuzumab |
| 11.1.2.Trastuzumab |
| 11.1.3.Ado-trastuzumab emtansine |
| 11.1.4.Lapatinib |
| 11.1.5.Everolimus |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Retail Pharmacies |
| 11.2.3.Online Pharmacies |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America HER2 Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Pertuzumab |
| 12.1.2.Trastuzumab |
| 12.1.3.Ado-trastuzumab emtansine |
| 12.1.4.Lapatinib |
| 12.1.5.Everolimus |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Retail Pharmacies |
| 12.2.3.Online Pharmacies |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Novartis AG (Switzerland) |
| 13.2.2.Pfizer Inc. (U.S.) |
| 13.2.3.Biocon Limited (India) |
| 13.2.4.Abnova Corporation (Taiwan) |
| 13.2.5.Genentech Inc. (U.S.) |
| 13.2.6.InvivoGen (U.S.) |
| 13.2.7.Bio-Techne Corporation (U.S.) |
| 13.2.8.Celltrion Healthcare (South Korea) |
| 13.2.9.Puma Biotechnology (U.S.) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.